Trials / Completed
CompletedNCT00470054
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVE I. Determine the efficacy of dasatinib in patients with relapsed small cell lung cancer. SECONDARY OBJECTIVE II. Determine the objective response rate (complete and partial response) in patients treated with this drug. III. Determine the overall survival of patients treated with this drug. IV. Determine the toxicity of this drug in these patients. OUTLINE: Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at least every 3 months for 1 year and then every 6 months for 3 years.
Conditions
- Extensive Stage Small Cell Lung Cancer
- Limited Stage Small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib | Given PO |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2009-02-01
- Completion
- 2013-04-01
- First posted
- 2007-05-07
- Last updated
- 2015-05-05
- Results posted
- 2013-04-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00470054. Inclusion in this directory is not an endorsement.